Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PRAX | PRESS-RELEASE | bullish | 8/10 | Praxis Precision Medicines announced FDA acceptance of its NDA for relutrigine, a first-in-class therapy for SCN2A and S | Mar 30, 2026 |
| INMB | PRESS-RELEASE | mixed | 6/10 | INmune Bio reported a net loss of $45.9 million for 2025, wider than the $42.1 million loss in 2024, driven by a $16.5 m | Mar 30, 2026 |
| FTLF | PRESS-RELEASE | neutral | 3/10 | FitLife Brands announced it will report its Q4 2025 financial results on March 31, 2026, followed by an investor confere | Mar 30, 2026 |
| TPST | PRESS-RELEASE | mixed | 6/10 | Tempest Therapeutics reported financial results for 2025, highlighted by a significant reduction in net loss from $41.8M | Mar 30, 2026 |
| CANF | PRESS-RELEASE | bullish | 7/10 | Can-Fite BioPharma announced that its veterinary partner Vetbiolix has completed enrollment in a Phase 2 trial of Piclid | Mar 30, 2026 |
| RPRX | PRESS-RELEASE | neutral | 4/10 | Royalty Pharma announced a $500 million R&D co-funding agreement with Johnson & Johnson to advance JNJ-4804, an investig | Mar 30, 2026 |
| UNCY | PRESS-RELEASE | mixed | 6/10 | Unicycive Therapeutics reported its 2025 financial results, showing a narrower net loss of $26.6M (-$1.67/share) versus | Mar 30, 2026 |
| ELAB | PRESS-RELEASE | mixed | 5/10 | PMGC Holdings reported a 43% increase in total assets to $12.87 million and a rise in shareholders' equity to $7.84 mill | Mar 30, 2026 |
| CNTB | PRESS-RELEASE | neutral | 5/10 | Connect Biopharma announced a private placement of 6,130,000 ordinary shares at $3.25 per share, raising approximately $ | Mar 30, 2026 |
| PDSB | PRESS-RELEASE | mixed | 6/10 | PDS Biotechnology reported financial results for 2025 and provided a clinical update, including a Phase 3 trial amendmen | Mar 30, 2026 |
| AURA | PRESS-RELEASE | mixed | 5/10 | Aura Biosciences reported Q4 and full-year 2025 financial results, highlighting accelerated enrollment in its Phase 3 Co | Mar 30, 2026 |
| NRXP | PRESS-RELEASE | bullish | 6/10 | NRx Pharmaceuticals' subsidiary Hope Therapeutics partnered with Emobot Health to deploy an AI-powered 'Depression Therm | Mar 30, 2026 |
| NMRA | PRESS-RELEASE | mixed | 5/10 | Neumora Therapeutics reported Q4 and full-year 2025 financial results with reduced R&D and G&A expenses, resulting in a | Mar 30, 2026 |
| RVPH | PRESS-RELEASE | mixed | 6/10 | Reviva Pharmaceuticals reported financial results for 2025, showing a reduced net loss of $19.9M compared to $29.9M in 2 | Mar 30, 2026 |
| MLTX | PRESS-RELEASE | bullish | 8/10 | MoonLake Immunotherapeutics announced positive long-term Week 40 results from its Phase 3 VELA-1 and VELA-2 trials of so | Mar 28, 2026 |
| ROIV | PRESS-RELEASE | bullish | 8/10 | Roivant Sciences subsidiary Priovant Therapeutics announced positive Phase 3 VALOR trial results for brepocitinib in der | Mar 28, 2026 |
| BIIB | PRESS-RELEASE | bullish | 8/10 | Biogen announced positive Phase 2 results from the AMETHYST study of litifilimab in cutaneous lupus erythematosus (CLE), | Mar 28, 2026 |
| ALMS | PRESS-RELEASE | bullish | 8/10 | Alumis Inc. announced positive Phase 3 results for envudeucitinib, a highly selective oral TYK2 inhibitor, in moderate-t | Mar 28, 2026 |
| KYMR | PRESS-RELEASE | bullish | 7/10 | Kymera Therapeutics announced positive Phase 1b trial results for KT-621, an oral STAT6 degrader, showing deep target de | Mar 28, 2026 |
| CLDI | PRESS-RELEASE | mixed | 5/10 | Calidi Biotherapeutics reported Q4 and full-year 2025 financial results, showing a narrowed net loss per share despite a | Mar 27, 2026 |
| ENTX | PRESS-RELEASE | mixed | 5/10 | Entera Bio reported financial results for 2025, showing increased net loss and R&D spending as it advances its oral pept | Mar 27, 2026 |
| CUE | PRESS-RELEASE | neutral | 3/10 | Cue Biopharma appointed Lucinda Warren as interim president and CEO following the departure of Usman Azam. Warren, previ | Mar 27, 2026 |
| MNPR | PRESS-RELEASE | bullish | 7/10 | Monopar Therapeutics reported its 2025 financial results, showing a reduced net loss and a strengthened balance sheet wi | Mar 27, 2026 |
| ARTL | PRESS-RELEASE | neutral | 5/10 | Artelo Biosciences announced a private placement of 3,188,407 shares (or pre-funded warrants) and accompanying warrants | Mar 27, 2026 |
| CLDX | PRESS-RELEASE | bullish | 8/10 | Celldex Therapeutics presented positive Phase 2 data for barzolvolimab in chronic spontaneous urticaria (CSU), cold urti | Mar 27, 2026 |
| PVLA | PRESS-RELEASE | mixed | 6/10 | Palvella Therapeutics presented two posters at the 2026 American Academy of Dermatology meeting: one highlighting the te | Mar 27, 2026 |
| ACRS | PRESS-RELEASE | bullish | 8/10 | Aclaris Therapeutics released additional Phase 2a trial data for its investigational oral drug ATI-2138 in patients with | Mar 27, 2026 |
| ANAB | PRESS-RELEASE | mixed | 7/10 | AnaptysBio is spinning off its biopharma operations into First Tracks Biotherapeutics, which secured $80 million in gros | Mar 27, 2026 |
| QNTM | PRESS-RELEASE | mixed | 6/10 | Quantum BioPharma reported its 2025 financial results, highlighting a reduction in operating expenses to $15.3M from $16 | Mar 27, 2026 |
| SNTI | PRESS-RELEASE | mixed | 6/10 | Senti Biosciences reported Q4 and full-year 2025 financial results, showing a narrowed net loss compared to the prior ye | Mar 27, 2026 |